{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T04:52:04Z","timestamp":1780462324718,"version":"3.54.1"},"reference-count":33,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2006,12,8]],"date-time":"2006-12-08T00:00:00Z","timestamp":1165536000000},"content-version":"vor","delay-in-days":7,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Risk Analysis"],"published-print":{"date-parts":[[2006,12]]},"abstract":"<jats:p>Inherent in the decision to launch the Global Polio Eradication Initiative in 1988 was the expectation for many people that immunization against poliomyelitis would eventually simply stop, as had been the case with smallpox following its eradication in 1977. However, the strategies for managing the risks associated with a \u201cpolio\u2010free\u201d world must be continuously refined to reflect new developments, particularly in our understanding of the live polioviruses in the oral poliovirus vaccine (OPV) and in the international approach to managing potential biohazards. The most important of these developments has been the confirmation in 2000 that vaccine\u2010derived polioviruses (VDPVs) can circulate and cause polio outbreaks, making the use of OPV after interruption of wild poliovirus transmission incompatible with a polio\u2010free world. A comprehensive strategy has been developed to minimize the risks associated with eventual OPV cessation, centered on appropriate long\u2010term biocontainment of poliovirus stocks (whether for vaccine production, diagnosis, or research), the controlled reintroduction of any live poliovirus vaccine (i.e., from an OPV stockpile), and appropriate use of the inactivated poliovirus vaccine (IPV). Although some aspects of this risk management strategy are still debated, there is wide agreement that no strategy would entirely eliminate the potential risks to a polio\u2010free world. The current strategy for risk management in a polio\u2010free world will continue to evolve with better characterization of these risks and the development of more effective approaches both to reduce those risks and to limit their consequences should they occur.<\/jats:p>","DOI":"10.1111\/j.1539-6924.2006.00840.x","type":"journal-article","created":{"date-parts":[[2006,12,8]],"date-time":"2006-12-08T21:02:50Z","timestamp":1165611770000},"page":"1441-1448","source":"Crossref","is-referenced-by-count":36,"title":["Risk Management in a Polio\u2010Free World"],"prefix":"10.1111","volume":"26","author":[{"given":"R.","family":"Bruce Aylward","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland W.","family":"Sutter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve L.","family":"Cochi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly M.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamid","family":"Jafari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Heymann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,12,8]]},"reference":[{"key":"e_1_2_8_2_2","volume-title":"The Eradication of Infectious Diseases. Dahlem Workshop Reports","author":"Dowdle W. R.","year":"1997"},{"issue":"2","key":"e_1_2_8_3_2","first-page":"1","article-title":"Global disease elimination and eradication as public health strategies","volume":"76","author":"Goodman R. A.","year":"1998","journal-title":"Bulletin of the World Health Organization"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1124959"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.312.5775.832"},{"key":"e_1_2_8_6_2","volume-title":"Global Eradication of Poliomyelitis by the year 2000","author":"World Health Assembly","year":"1988"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-199103000-00011"},{"key":"e_1_2_8_8_2","first-page":"35","article-title":"Global eradication of poliomyelitis: Benefit\u2010cost analysis","volume":"74","author":"Bart K. J.","year":"1996","journal-title":"Bulletin of the World Health Organization"},{"key":"e_1_2_8_9_2","volume-title":"Financial Resource Requirements 2006\u20132008","author":"Global Polio Eradication Initiative","year":"2006"},{"key":"e_1_2_8_10_2","first-page":"65","article-title":"Strategies for poliomyelitis eradication in developing countries","volume":"21","author":"De Quadros C. A.","year":"1993","journal-title":"Public Health Reviews"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)92472-4"},{"key":"e_1_2_8_12_2","first-page":"651","volume-title":"Vaccines","author":"Sutter R. W.","year":"2003"},{"key":"e_1_2_8_13_2","unstructured":"The Global Polio Eradication Initiative. Available athttp:\/\/www.polioeradication.org\/casecount.asp(accessed February 25 2006)."},{"key":"e_1_2_8_14_2","first-page":"95","article-title":"Transmission of wild poliovirus type 2\u2014Apparent global interruption","volume":"76","author":"World Health Organization","year":"2001","journal-title":"Weekly Epidemiological Record"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.91.1.146"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/122.4.303"},{"key":"e_1_2_8_17_2","volume-title":"Report of the Interim Meeting of the Technical Consultative Group (TCG) on the Global Eradication of Poliomyelitis","author":"Vaccines & Biologicals Department","year":"2004"},{"issue":"5","key":"e_1_2_8_18_2","first-page":"1","article-title":"Poliomyelitis prevention in the United States. Updated recommendations of the Advisory Committee on Immunization Practices","volume":"49","author":"Centers for Disease Control and Prevention","year":"2000","journal-title":"MMWR. Morbidity and Mortality Weekly Report"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.276.12.967"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1068284"},{"key":"e_1_2_8_21_2","first-page":"16","article-title":"Circulating vaccine\u2010derived polioviruses: Current state of knowledge","volume":"82","author":"Kew O. M.","year":"2004","journal-title":"Bulletin of the World Health Organization"},{"key":"e_1_2_8_22_2","first-page":"1","article-title":"Poliovirus infections in four unvaccinated children\u2014Minnesota, August\u2013October 2005","volume":"54","author":"Centers for Disease Control and Prevention","year":"2005","journal-title":"MMWR. Morbidity and Mortality Weekly Report"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1086\/498166"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1086\/338262"},{"key":"e_1_2_8_25_2","volume-title":"Report of an Informal Consultation on the Identification and Management of Vaccine\u2010derived Polioviruses (VDPVs)","author":"Vaccines and Biologicals","year":"2004"},{"key":"e_1_2_8_26_2","first-page":"401","article-title":"Conclusions and recommendations of the ad hoc advisory committee on poliomyelitis eradication, Geneva, 21\u201322 September 2004","volume":"79","author":"Polio Eradication Initiative","year":"2004","journal-title":"Weekly Epidemiological Record"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/175.Supplement_1.S286"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1539-6924.2006.00827.x"},{"key":"e_1_2_8_29_2","article-title":"Consequences of release\/reintroduction of polioviruses in different geographic areas after OPV cessation","author":"Fine P. E. M.","year":"2006","journal-title":"Risk Analysis"},{"key":"e_1_2_8_30_2","volume-title":"Cessation of Routine Oral Polio Vaccine (OPV) Use After Global Polio Eradication. Framework for National Policy Makers in OPV\u2010Using Countries","author":"Polio Eradication Initiative","year":"2005"},{"key":"e_1_2_8_31_2","first-page":"241","article-title":"Introduction of inactivated poliovirus vaccine into oral poliovirus vaccine\u2010using countries. WHO Position Paper","volume":"78","author":"World Health Organization","year":"2004","journal-title":"Weekly Epidemiological Records"},{"key":"e_1_2_8_32_2","first-page":"137","article-title":"Inactivated poliovirus vaccines (IPV) following oral poliovirus vaccine (OPV) cessation. Supplemental WHO Position Paper","volume":"81","author":"World Health Organization","journal-title":"Weekly Epidemiological Records"},{"issue":"1","key":"e_1_2_8_33_2","first-page":"9","article-title":"Cost analysis of post\u2010polio certification immunization policies","volume":"82","author":"Sangrujee N.","year":"2004","journal-title":"Bulletin of the World Health Organization"},{"key":"e_1_2_8_34_2","first-page":"410","article-title":"Conclusions and recommendations of the Advisory Committee on Poliomyelitis Eradication, Geneva, 11\u201312 October 2005","volume":"80","author":"Polio Eradication Initiative","year":"2005","journal-title":"Weekly Epidemiological Records"}],"container-title":["Risk Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1539-6924.2006.00840.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1539-6924.2006.00840.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1539-6924.2006.00840.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/j.1539-6924.2006.00840.x","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1539-6924.2006.00840.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T20:49:26Z","timestamp":1694378966000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1539-6924.2006.00840.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,12]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2006,12]]}},"alternative-id":["10.1111\/j.1539-6924.2006.00840.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1539-6924.2006.00840.x","archive":["Portico"],"relation":{},"ISSN":["0272-4332","1539-6924"],"issn-type":[{"value":"0272-4332","type":"print"},{"value":"1539-6924","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,12]]}}}